Form 4: Lexicon Pharmaceuticals Executive Alan J. Main Reports Stock Transactions

Alan J. Main, EVP of Innovation & Chemical Sciences at Lexicon Pharmaceuticals, reports the vesting and conversion of restricted stock units into common stock, along with a portion of shares withheld for tax obligations.

Summary

• On February 28, 2024, Alan J. Main, EVP of Innovation & Chemical Sciences at Lexicon Pharmaceuticals, executed transactions involving restricted stock units and common stock.
• Main converted 8,977, 25,666, and 32,903 restricted stock units into common stock.
• A portion of the issued shares, totaling 24,408, were withheld by the company to satisfy tax obligations at a price of $2.62 per share.
• Following these transactions, Main directly owns 255,724 shares of Lexicon Pharmaceuticals common stock.
• Main also owns 0, 25,667, and 65,807 restricted stock units.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors monitor these filings to understand management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.

Key Dates